Cefmetazole sodium

Functions and indications:
It is a beta-lactam antibiotic and a cephalosporin drug. It is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Streptococcus, Bacteroides, and Prevotella (except Prevotella biloba) that are sensitive to ceftriaxone sodium: 1. Sepsis. 2. Acute bronchitis, pneumonia, lung abscess, empyema, and secondary infection of chronic respiratory diseases. 3. Cystitis, pyelonephritis; peritonitis; cholecystitis, cholangitis. 4. Bartholinitis, intrauterine infection, adnexitis, and parametrial tissue inflammation. 5. Cellulitis around the jaw and jaw inflammation.
Usage and dosage:
The usage and dosage of this product may vary in different dosage forms and specifications. Please read the specific drug instructions for use or follow the doctor’s advice. Cefmetazole Sodium for Injection: 1. Adults, 1-2g (titer) per day, divided into 2 intravenous injections or intravenous drips. 2. Children, 25-100mg (titer)/kg body weight per day, divided into 2-4 intravenous injections or intravenous drips. 3. For refractory or severe infections, the daily dose can be increased to 4g (titer) for adults and 150mg (titer)/kg body weight for children according to symptoms, divided into 2-4 doses. 4. For intravenous injection, 1g (titer) of this product is dissolved in 10mg of distilled water for injection, saline or glucose injection, and injected slowly. In addition, this product can also be added to the rehydration for intravenous drip. At this time, distilled water for injection should not be used to dissolve it because the osmotic pressure of the solution is not isotonic. 5. Usage and Dosage Precautions: (1) For patients with severe renal impairment, the dosage and dosing interval should be appropriately adjusted, and the drug should be used with caution (refer to [Cautionary Use] and [Pharmacokinetics]). (2) When using this product, in principle, a drug sensitivity test should be performed, and the use of the drug should be limited to the shortest time necessary to treat the disease [to prevent the emergence of drug-resistant bacteria, etc.]. 6. Instructions for use: (1) Preparation method: When preparing intravenous drips, refer to the precautions recorded in the above-mentioned Usage and Dosage column. (2) Administration: When a large amount of intravenous administration is given, it may cause vascular irritation pain, so full attention should be paid to the preparation of the injection solution, the injection site and the injection method, and the injection should be injected as slowly as possible.
Adverse reactions:
(This item includes adverse reactions whose incidence cannot be calculated) Among a total of 27,356 cases, 841 cases (3.07%) reported adverse reactions, mainly AST (GOT) increase (0.94%), ALT (GPT) increase (0.90%), rash (0.82%), nausea and vomiting (0.20%), etc. Major adverse reactions: 1. Rarely cause shock (less than 0.01%), allergic reaction symptoms (discomfort, oral abnormality, wheezing, dizziness, urge to defecate, tinnitus, sweating, etc.) (incidence unknown). Therefore, it should be observed carefully. If abnormalities occur, the drug should be discontinued immediately and appropriate treatment should be given. 2. Skin mucosal eye syndrome (Stevens-Johnson syndrome) (incidence unknown) and toxic epidermal necrosis (Lyell syndrome) (incidence unknown) may occur. Once similar symptoms are found, the drug should be discontinued immediately and appropriate treatment should be given. 3. Severe renal damage such as acute renal failure (incidence unknown) may occur, so careful observation and regular examination of renal function should be given. If BUN and blood creatinine increase, the drug should be discontinued immediately and appropriate treatment should be given. 4. Hepatitis (incidence unknown), liver dysfunction (incidence unknown), jaundice (incidence unknown): Because there are hepatitis and liver dysfunction manifestations such as significant increases in AST (GOT) and ALT (GPT), it should be observed carefully. If abnormalities occur, the drug should be discontinued immediately and appropriate treatment should be given. 5. Agranulocytosis (incidence unknown), hemolytic anemia (incidence unknown), and thrombocytopenia (incidence unknown) may occur. Therefore, it should be observed carefully. If abnormalities occur, the drug should be discontinued immediately and appropriate treatment should be given. 6. Pseudomembranous colitis with blood in stool is rare (less than 0.01%) (initial symptoms: abdominal pain, frequent diarrhea). Therefore, it should be observed carefully. If abnormalities occur, the drug should be discontinued immediately and appropriate treatment should be given. 7. Interstitial pneumonia (incidence unknown) and pulmonary infiltration (PIE) syndrome with symptoms such as fever, cough, dyspnea, abnormal chest X-ray examination, and eosinophilia (incidence unknown) may occur. Once similar symptoms occur, the drug should be discontinued immediately and appropriate treatment should be given, such as the use of adrenocortical hormones.
Contraindications:
1. Patients with a history of anaphylactic shock to the ingredients of this product are prohibited from using this product. 2. Patients with a history of allergy to the ingredients contained in this product or cephalosporin antibiotics should not be given this drug in principle, and should be used with caution when they have to be used.